Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial.
mRNA-1345 RSV Vaccine + High-Dose Flu Vaccine in Older Adults: Coadministration Efficacy & Safety
Quick Take: Coadministration of mRNA-1345 RSV vaccine with a high-dose quadrivalent influenza vaccine in adults 65+ demonstrates non-inferior immunogenicity for both vaccines and an acceptable safety profile, suggesting a viable strategy for combined administration.
💡 Clinical Impact
- Mechanistic Why: This data necessitates a consideration of simultaneous vaccination strategies to enhance adherence and reduce healthcare burden. The mRNA platform's flexibility allows for potential polyvalent vaccine development, and the observed antibody responses suggest robust activation of both humoral immunity against RSV and influenza without significant interference.
- Clinical/Systemic Benefit: Streamlining vaccination schedules by combining RSV and influenza shots can improve patient compliance, especially in the vulnerable 65+ population, and potentially optimize clinic workflow by reducing the number of required visits.
📊 Evidence Breakdown
Evidence Grade: 🟢 9/10 (Phase III RCT)
Analysis: This is a high-quality Phase III randomized, observer-blinded, placebo-controlled trial, the gold standard for vaccine efficacy and safety assessment. The study design directly addresses the primary endpoint of non-inferior immunogenicity, which was met for both vaccines when coadministered. The safety profile appears manageable, though long-term durability of the combined immune response and the precise impact of any subtle immunomodulatory effects are still areas requiring ongoing surveillance.
Note: While non-inferiority in immunogenicity is established, direct comparative efficacy against actual RSV and influenza disease endpoints will be crucial for definitive practice-changing recommendations. The study does not provide this comparative efficacy data directly.
🩺 Practice Recommendation
[Adjunctive Therapy]: Confirm eligibility and recommend coadministration of mRNA-1345 (if approved and indicated) with the high-dose quadrivalent influenza vaccine for patients 65 years and older.
- Monday Morning Action: Review your current RSV and influenza vaccination protocols for patients 65+. Be prepared to discuss the option of coadministration of the mRNA-1345 RSV vaccine with the high-dose influenza vaccine, provided both are approved and indicated for the individual patient, to improve vaccination uptake and convenience.